BioCentury
ARTICLE | Company News

ImQuest, Samjin Pharmaceutical Co. Ltd. deal

May 1, 2006 7:00 AM UTC

ImQuest received exclusive worldwide rights to develop and commercialize Samjin's preclinical piperazine small molecules to treat various cancers. The compounds are microtubule synthesis and cell cycl...